Form 4: PTC Therapeutics CEO Matthew Klein Sells Shares to Cover Tax Obligations
SEC Form 4
PTC Therapeutics CEO Matthew Klein sold 1,307 shares of common stock on April 17, 2024, to cover tax obligations related to the vesting of restricted stock units.
Summary
- On April 17, 2024, Matthew B. Klein, CEO of PTC Therapeutics, sold 1,307 shares of the company's common stock.
- The sale was executed at a price of $25.135 per share.
- The transaction was conducted to cover tax withholding obligations associated with the vesting of 2,500 restricted stock units (RSUs) from a grant made on April 16, 2020.
- Following the transaction, Klein directly owns 229,168 shares of PTC Therapeutics common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral as the transaction is a routine sale of shares to cover tax obligations, which is a common practice.
Industry Context
Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among corporate executives and are generally not indicative of a negative outlook on the company's future.
Key Dates
| Date | Description |
|---|---|
| 04/16/2020 | Date of original grant of 10,000 RSUs |
| 04/17/2024 | Date of stock sale transaction |
| 04/19/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.